No stem-cell therapy for muscular dystrophy has received FDA approval or EMA approval as a licensed medicinal product. All current interventions remain investigational or available through clinical-trial programmes. Some centres market unproven stem-cell treatments directly to patients, but these fall outside regulated pathways and lack rigorous safety oversight. Regulatory agencies have not yet cleared a muscular-dystrophy-specific stem-cell product, reflecting the complexity of the disease and the limited efficacy data from trials. Patients should verify whether any proposed treatment is part of a registered clinical trial under regulatory supervision.
Muscular dystrophies encompass a family of progressive genetic disorders affecting muscle strength and integrity. Stem-cell research investigates whether placental mesenchymal stem cells (MSCs) and fetal stem cells can integrate into damaged muscle tissue, secrete anti-inflammatory factors, and halt the cascade of degeneration characteristic of conditions like Duchenne muscular dystrophy. The approach targets both direct muscle regeneration through cell fusion and paracrine effects that reduce inflammation and fibrosis. With 26 registered trials and 4 currently recruiting participants, early-phase data suggests MSCs may slow progression, particularly when infused systemically or injected locally into affected muscles. The neuromuscular pathology — characterised by dystrophin loss and calcium dysregulation — creates a uniquely hostile environment for transplanted cells, making efficacy variable and recovery timescales extended.
Sunt un candidat? → · Muscular Dystrophy: full overview → · Cost Distrofie Musculară → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită